Cargando…

PKPD Modeling of Predictors for Adverse Effects and Overall Survival in Sunitinib-Treated Patients With GIST

A modeling framework relating exposure, biomarkers (vascular endothelial growth factor (VEGF), soluble vascular endothelial growth factor receptor (sVEGFR)-2, -3, soluble stem cell factor receptor (sKIT)), and tumor growth to overall survival (OS) was extended to include adverse effects (myelosuppre...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hansson, E K, Ma, G, Amantea, M A, French, J, Milligan, P A, Friberg, L E, Karlsson, M O
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2013
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3868978/ https://www.ncbi.nlm.nih.gov/pubmed/24304978 http://dx.doi.org/10.1038/psp.2013.62

Ejemplares similares

PKPD Modeling of VEGF, sVEGFR-2, sVEGFR-3, and sKIT as Predictors of Tumor Dynamics and Overall Survival Following Sunitinib Treatment in GIST
por: Hansson, E K, et al.
Publicado: (2013)

PK‐PD modeling of individual lesion FDG‐PET response to predict overall survival in patients with sunitinib‐treated gastrointestinal stromal tumor
por: Schindler, E, et al.
Publicado: (2016)

Evaluation of nilotinib in advanced GIST previously treated with imatinib and sunitinib
por: Cauchi, C., et al.
Publicado: (2011)

Effect of gastrointestinal resection on sunitinib exposure in patients with GIST
por: de Wit, Djoeke, et al.
Publicado: (2014)

IL8 polymorphisms and overall survival in pazopanib- or sunitinib-treated patients with renal cell carcinoma
por: Xu, C-F, et al.
Publicado: (2015)

PhysiPKPD: A pharmacokinetics and pharmacodynamics module for PhysiCell
por: Bergman, Daniel, et al.
Publicado: (2022)

Multistate model for pharmacometric analyses of overall survival in HER2‐negative breast cancer patients treated with docetaxel
por: Krishnan, Sreenath M., et al.
Publicado: (2021)

PKPD modeling of acquired resistance to anti-cancer drug treatment
por: Eigenmann, Miro J., et al.
Publicado: (2017)

Considerations for Intravenous Anesthesia Dose in Obese Children: Understanding PKPD
por: Morse, James Denzil, et al.
Publicado: (2023)

PKPD Modeling of the Inoculum Effect of Acinetobacter baumannii on Polymyxin B in vivo
por: Chauzy, Alexia, et al.
Publicado: (2022)

Dutch Gastrointestinal Stromal Tumor (GIST) Registry Data Comparing Sunitinib with Imatinib Dose Escalation in Second-Line Advanced Non-KIT Exon 9 Mutated GIST Patients
por: Mohammadi, Mahmoud, et al.
Publicado: (2022)

Bayesian forecasting of tumor size metrics and overall survival
por: Krishnan, Sreenath M., et al.
Publicado: (2022)

Simultaneous pharmacokinetic/pharmacodynamic (PKPD) assessment of ampicillin and gentamicin in the treatment of neonatal sepsis
por: Gastine, Silke, et al.
Publicado: (2021)

A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients
por: Schindler, E, et al.
Publicado: (2017)

Adverse reactions of sorafenib, sunitinib, and imatinib in treating digestive system tumors
por: Fu, Yali, et al.
Publicado: (2018)

Real World Overall Survival of Patients With Metastatic Renal Cell Carcinoma Treated With Only Available Sunitinib and Pazopanib in First-Line Setting
por: Nikic, Predrag, et al.
Publicado: (2022)

A Minimal PKPD Interaction Model for Evaluating Synergy Effects of Combined NSCLC Therapies
por: Ionescu, Clara Mihaela, et al.
Publicado: (2020)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

P02-026 - Model-based characterization of the PKPD relationship for canakinumab in CAPS: a step towards personalized
por: Gautier, A, et al.
Publicado: (2013)

Analysis of adverse events of sunitinib in patients treated for advanced renal cell carcinoma
por: Domagała-Haduch, Małgorzata, et al.
Publicado: (2016)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J J, et al.
Publicado: (2018)

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC
por: Knox, J. J., et al.
Publicado: (2017)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
por: Rutkowski, Piotr, et al.
Publicado: (2017)

Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review
por: Tan, Siyuan, et al.
Publicado: (2018)

gPKPDSim: a SimBiology(®)-based GUI application for PKPD modeling in drug development
por: Hosseini, Iraj, et al.
Publicado: (2018)

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study
por: Rutkowski, Piotr, et al.
Publicado: (2012)

Long term survival results for gastric GIST: is laparoscopic surgery for large gastric GIST feasible?
por: Kim, Ki-Han, et al.
Publicado: (2012)

A GIST or not a GIST? That is the question
por: Chrysanthos, Nikolaos, et al.
Publicado: (2014)

First-line therapy with sunitinib in advanced renal cell carcinoma: interpretation of the overall survival data from asco 2008
por: Wood, L.
Publicado: (2009)

Survival in Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib With or Without Cryoablation
por: Gu, Cheng-Yuan, et al.
Publicado: (2021)

Serum immunoregulatory proteins as predictors of overall survival of metastatic melanoma patients treated with ipilimumab
por: Koguchi, Yoshinobu, et al.
Publicado: (2015)

Imatinib dose escalation versus sunitinib as a second line treatment in KIT exon 11 mutated GIST: a retrospective analysis
por: Vincenzi, Bruno, et al.
Publicado: (2015)

Synchronous double gastric tumors: GIST or not GIST
por: Sayida, Sa’d, et al.
Publicado: (2020)

3552 Advancing Glioblastoma (GBM) drug regimen development to support combination therapy through integrated PKPD modeling and simulation-based predictions
por: Adhikari, Saugat, et al.
Publicado: (2019)

Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α
por: Patil, S, et al.
Publicado: (2012)

Conditional disease-free survival in high-risk renal cell carcinoma treated with sunitinib
por: Shao, Ning, et al.
Publicado: (2019)

Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab
por: Gillen, J., et al.
Publicado: (2019)

GIST and Ghrelin: To Be or Not to Be?
por: Spiridon, Irene Alexandra, et al.
Publicado: (2021)

Time-dependent endpoints as predictors of overall survival in multiple myeloma
por: Félix, Jorge, et al.
Publicado: (2013)

Sunitinib: a novel tyrosine kinase inhibitor. A brief review of its therapeutic potential in the treatment of renal carcinoma and gastrointestinal stromal tumors (GIST)
por: Le Tourneau, Christophe, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_9lprkndn221o8mv0jitl72db4t